|
Market Closed -
London S.E.
23:35:16 28/08/2026 HKT
|
5-day change | 1st Jan Change | ||
| 11,970.00 GBX | -1.19% |
|
-2.21% | -13.20% |
| 06:53pm | IDEAYA Biosciences Plans Phase 3 Trial for Lung Cancer Therapy | MT |
| 03:39pm | Hutchmed Says Lung Cancer Therapy Improves Progression-Free Survival in China Phase 3 Trial | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Other Pharmaceuticals
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 252B | |||||
| 1,047B | |||||
| 646B | - | - | - | ||
| 451B | |||||
| 355B | |||||
| 291B |
- Stock Market
- Stocks
- AZN Stock
- Charts AstraZeneca PLC
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
